Guo Y C, DeSanto L, Osetinsky G V
Department of Otorhinolaryngology, Mayo Clinic.
Otolaryngol Head Neck Surg. 1989 Feb;100(2):95-8. doi: 10.1177/019459988910000203.
The nuclear DNA content was measured in formalin-fixed and deparaffined specimens of 296 oral, pharyngeal, and laryngeal squamous cell carcinomas from patients in whom the clinical outcome was known. One hundred ninety (64%) contained cells with abnormal DNA (DNA aneuploid or tetra/polypoid). Only 32% (60 of 190) of the patients with DNA nondiploid cancers survived 5 years, compared with 49% (52 of 106) of the patients with DNA diploid cancers. When the findings were controlled for clinical stage, patients whose tumors were DNA diploid had a survival advantage at each stage. Histologic grading showed less correlation, because only patients with well-differentiated carcinomas had a survival advantage if their tumors were DNA diploid. These data showed that determination of DNA content in cancers of the head and neck can offer prognostic information not provided by other means and enhance the diagnosis of cancer.
对296例口腔、咽和喉鳞状细胞癌患者经福尔马林固定和脱蜡处理的标本进行了核DNA含量测定,这些患者的临床结局已知。190例(64%)含有DNA异常(DNA非整倍体或四倍体/多倍体)的细胞。DNA非二倍体癌症患者中只有32%(190例中的60例)存活5年,而DNA二倍体癌症患者的这一比例为49%(106例中的52例)。当对临床分期进行校正后发现,肿瘤为DNA二倍体的患者在每个分期都具有生存优势。组织学分级的相关性较小,因为只有高分化癌患者,如果其肿瘤为DNA二倍体,则具有生存优势。这些数据表明,对头颈部癌症进行DNA含量测定可提供其他方法无法提供的预后信息,并能加强癌症的诊断。